TB-500: Evidence, Safety, Dosing, and Access

TB-500 is a synthetic peptide fragment related to thymosin beta-4, a naturally occurring peptide involved in cell structure and repair signaling. Human evidence for TB-500 itself is limited, with much of the research coming from thymosin beta-4, related fragments, preclinical models, and sports-medicine reviews rather than large clinical trials 10.

What it is

TB-500 is a synthetic peptide fragment related to thymosin beta-4, also written thymosin β4 or TB4. In plain language, it belongs to a family of small peptides that are discussed in cell-movement, tissue-repair, and sports-medicine research 12.

TB-500, thymosin beta-4, and TB4 fragments

Thymosin beta-4 is a naturally occurring peptide that has been reviewed for its post-translational modifications and broad biology 10. TB-500 is often discussed as a thymosin beta-4 fragment, but the exact fragment, formulation, route, and setting matter. A finding about thymosin beta-4 does not automatically prove that a TB-500 product has the same effect in people 6.

In patient searches, TB-500 often appears near BPC-157 because both are discussed in tissue-repair and sports-medicine settings. We compare them in more detail in our guide to TB-500 vs BPC-157, but the short version is that both have important evidence gaps and product-quality risks.

How this page grades the evidence

This page uses the assigned evidence grade for TB-500 from the supplied evidence set: grade B. That grade reflects the quantity and design of indexed research, not whether TB-500 works, and not whether it is safe.

The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

Mechanism of action

TB-500 is proposed to work through thymosin beta-4-related biology, especially actin binding and cell-movement pathways. In humans, the exact mechanism for TB-500 as a treatment is not established.

Actin binding and cell-movement biology

Actin is a structural protein that helps cells hold shape and move. Beta-thymosins are small acidic peptides with multiple biological functions, including actin-related cellular functions that are relevant to proposed repair mechanisms 12.

This is why TB-500 is often discussed around cell migration, tissue repair, and musculoskeletal injury. But a proposed mechanism is not the same as a proven clinical outcome, and sports-medicine reviews continue to describe peptide evidence and safety as uneven across approved and unapproved peptide therapies 6.

Tissue repair, inflammation, and blood-vessel signaling: what is preclinical versus human

Cell research has studied thymosin beta-4 in human brain endothelial-cell dysfunction models, but that is in-vitro evidence, not proof of a human clinical benefit 9. Animal research has also studied thymosin β4-derived peptides in in-vitro models and 5 × FAD mice for neuroinflammation and neurite atrophy, but animal results do not show that TB-500 improves memory or inflammation in humans 11.

A rat study evaluated BPC-157 and TB-500 in Achilles tendon healing with histopathological and biomechanical outcomes; because this was an animal study, it should not be read as proof of human injury recovery 8. If you are comparing recovery peptides, our article on BPC-157 and TB-500 side effects explains why safety questions are as important as possible mechanisms.

Evidence

TB-500 is assigned evidence grade B under the supplied rubric. That grade is about the design and count of studies, not a conclusion that TB-500 is effective or safe.

Evidence grade rubric: A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

The strongest human signal in the supplied evidence is not a completed TB-500 treatment trial. A randomized human study in chronic ischemic heart failure reported that increases in plasma Tβ4 after intracardiac cell therapy were associated with symptomatic improvement; that is thymosin beta-4 association data, not proof that TB-500 treats heart disease 2.

The supplied evidence set also includes a clinical-trial record that is not direct TB-500 therapeutic evidence for injury repair or cardiovascular care, so it should not be used to claim TB-500 benefit 1. Reviews in orthopaedics and sports medicine discuss therapeutic peptides, injectable peptide therapy, and challenges around evidence quality, safety, and unapproved peptide use 4, 5, 6.

Why TB-500 is assigned evidence grade B

The grade is B because the supplied PubMed counts include one randomized human trial or two or more human clinical trials. For a patient, the important point is more cautious: grade B does not mean large, direct, positive TB-500 trials exist for injury recovery, muscle growth, heart health, or inflammation.

A registered Phase 1/2 trial is recruiting to study TB-500, described as thymosin beta 4 17-23 fragment, for cardiovascular biomarkers in stable ASCVD. Recruiting status means the study is ongoing and does not yet provide completed efficacy or safety results 13.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-07.

Reported dosing ranges

TB-500 dosing is not established from the supplied published human evidence. The table below reports what the supplied sources can support; it is not a dosing plan and should not be used to start, inject, or combine peptide products.

Why published dosing information is not the same as medical dosing advice

A dose in a study is chosen for that study’s design, population, route, and endpoints. It is not the same as medical advice for an individual person, especially when the clinical evidence is limited and the product source may vary 6.

Dosing range chart: route, study context, and evidence limits

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-07. See the full legal-status tracker for every compound we follow.

Safety

TB-500 safety is not well defined in large human trials. The honest answer is that human safety data are limited, and product quality can change the risk more than many people realize.

What human safety data can and cannot tell us

The supplied human literature does not establish a clear adverse-effect rate for TB-500 in patients. Reviews of approved and unapproved peptide therapies in musculoskeletal injury and athletic performance describe safety and efficacy as key unresolved issues for many peptide products 6.

Because thymosin-related peptides are discussed around tissue repair, inflammation, and blood-vessel signaling, patients with cancer history, immune disease, cardiovascular disease, pregnancy, planned surgery, or active infection should not self-experiment. Those are clinical situations where mechanism uncertainty and limited safety data matter 4, 6.

Risks of unverified peptide products

A major safety issue is the supply chain. Products sold as “research use only” may not be made for people, and unverified peptide products can create risks around sterility, identity, impurity, concentration, and contamination; sports-medicine reviews flag these concerns when discussing unapproved peptide therapies 6, 7.

If you are reading seller pages or group-buy forums, pause before you inject anything. Our guide to peptide group buys explains why low price and lab-looking labels are not the same as clinician oversight, sterile compounding, or a prescription process.

Interactions

TB-500 interaction studies have not been published in the supplied evidence set. That is not reassurance; it means drug, supplement, and condition interactions remain poorly characterized.

Heart disease, cancer history, immune conditions, pregnancy, and surgery

People with heart disease should discuss thymosin-related peptides with a clinician because the supplied human heart-failure study measured plasma Tβ4 changes after intracardiac cell therapy, not TB-500 use as a standard heart treatment 2. A recruiting trial is studying TB-500 for cardiovascular biomarkers in stable ASCVD, but recruiting trials do not answer safety or benefit questions yet 13.

Cancer history, immune conditions, pregnancy, breastfeeding, and upcoming surgery deserve extra caution because the proposed biology involves repair signaling, inflammation, and cell movement. The supplied reviews emphasize that unapproved peptide therapies need careful evidence and safety review rather than casual self-use 4, 6.

Other medications, supplements, and injectable products

The supplied sources do not document specific TB-500 interactions with anticoagulants, antiplatelet drugs, hormone therapy, GLP-1 medications, NSAIDs, supplements, or other injectable peptides. A clinician still needs the full medication list because absence of published interaction studies is not the same as absence of risk 6.

How to obtain it legally

TB-500 access should start with a clinician evaluation, not a shopping cart. A safer process includes a health history, medication review, discussion of goals, screening for higher-risk conditions, and a clear explanation of what is known and unknown.

What a clinician evaluation should include

A clinician should ask why you are considering a peptide, what injury or symptom you are trying to address, what diagnoses you have, and what medications or supplements you use. For musculoskeletal concerns, orthopaedic and sports-medicine reviews stress that peptide claims need to be separated from the quality of evidence behind them 4, 5, 6.

What a licensed pharmacy is responsible for

When a prescription treatment is clinically appropriate, the safer supply chain is a licensed clinician and a state-licensed pharmacy, not an anonymous peptide seller. Licensed pharmacy practice is meant to address identity, sterility, labeling, and patient-specific dispensing in ways that research-chemical vendors are not designed to provide.

What a research-chemical vendor is not

A research-chemical vendor is not your clinician, pharmacy, or follow-up plan. “Research use only” material is not made for human treatment, and the risks include wrong ingredient, wrong concentration, impurities, non-sterile handling, and no medical monitoring 6, 7.

Does Chia offer TB-500?

No. Chia does not list TB-500 in our current treatment catalog, so this page is education-only for TB-500. If you are researching peptide access, our guide on where to get peptide injections safely explains the broader process of clinician evaluation, prescription when appropriate, and pharmacy-based dispensing.

Chia does offer certain clinician-reviewed longevity options in our current catalog, including GHK-Cu cream, NAD+ injection or nasal spray, glutathione injection or nasal spray, and sermorelin injection, nasal spray, or tablets. Treatment through Chia starts with a 100% online health questionnaire reviewed by a licensed US provider; a prescription is never guaranteed, dosing is provider-guided, and medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.

If you are mainly trying to understand TB-500 before buying anything online, read our patient guide on whether you can buy TB-500 online and our deeper overview of the TB-500 peptide.

FAQ

Keep reading

Peptides

TB-500 vs BPC-157: What Patients Should Know Before Comparing Recovery Peptides

Peptides

Wolverine Stack Peptides: What BPC-157 and TB-500 Are, and What the Evidence Says

Peptides

TB4 Peptide: What It Is, How It Works, and What the Research Actually Shows